BOSTON, Dec. 7, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 9, 2024 at 9:45am Pacific time.
The public may access Mr. Simon's presentation here.
The live webcast can also be accessed under the Events & Presentations section of the Company's Investor Relations website. The replay of the presentation will be available for 30 days using the link provided above and on Investor Relations website shortly after the live event.
ABOUT HAEMONETICS
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts: | |
Olga Guyette, Sr. Director-Investor Relations & Treasury | David Trenk, Manager-Investor Relations |
(781) 356-9763 | (203) 733-4987 |
Media Contact: |
| Last Trade: | US$70.23 |
| Daily Change: | 2.04 2.99 |
| Daily Volume: | 769,132 |
| Market Cap: | US$3.530B |
May 08, 2025 February 24, 2025 February 06, 2025 August 15, 2024 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
